PhosPepPres
Financiado
Improving Peptide-Based Anti-Cancer Vaccines with Phosphatase Inhibitors
Peptides have great potential for vaccines. Peptide-based vaccines aim to increase the population and activity of pathogen/cancer-recognizing T cells by administering antigenic peptides carrying epitopes for major histocompatibili...
Peptides have great potential for vaccines. Peptide-based vaccines aim to increase the population and activity of pathogen/cancer-recognizing T cells by administering antigenic peptides carrying epitopes for major histocompatibility (MHC) class I and II. These peptides are endocytosed by dendritic cells (DCs), followed by intracellular proteolytic processing to release the epitopes, the loading of the epitopes on MHC, and finally the presentation to antigen-specific T cells. Despite numerous studies showing immunogenicity in preclinical settings, peptide-based vaccines have failed to show efficacy in clinical trials. One reason for this limited efficacy is that too low amounts of epitopes are presented on MHC. Thus, one way to improve peptide-based vaccines is to improve their intracellular processing for MHC presentation by DCs. In this project, we will explore a novel approach for increasing the cross-presentation efficiency. Moreover, we will perform pre-commercialization studies aimed at protecting the intellectual property, defining the commercialization strategy, and enhancing our industrial network. We expect that our strategy will raise interest, as many pharmaceutical companies are developing peptide-based vaccines.
ver más
Duración del proyecto: 21 meses
Fecha Inicio: 2023-04-05
Fecha Fin: 2025-01-31
Fecha Fin: 2025-01-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-04-05
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2022-POC2:
ERC PROOF OF CONCEPT GRANTS2
Cerrada
hace 2 años
Presupuesto
El presupuesto total del proyecto asciende a
150K€
Líder del proyecto
RIJKSUNIVERSITEIT GRONINGEN
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5